Attenuated Mengo virus: a new vector for live recombinant vaccines.
AUTOR(ES)
Altmeyer, R
RESUMO
Several features make Mengo virus an excellent candidate for use as a vaccine vector. The virus has a wide host range, including rodents, pigs, monkeys, and most likely humans, and expresses its genome exclusively in the cytoplasm of the infected cell. Stable attenuated strains exist which are deleted for part of the 5' noncoding region of the genome. Here we report an attenuated Mengo virus recombinant, vLCMG4, that encodes an immunodominant cytotoxic T-lymphocyte epitope of the lymphocytic choriomeningitis virus (LCMV) nucleo-protein. vLCMG4 induced protective immunity against lethal LCMV infection after a single, low-dose immunization in BALB/c mice and elicited an LCMV-specific CD8+ cytotoxic T lymphocyte response. This demonstrates the potential of recombinant Mengo virus vaccines to confer protection against infectious diseases by the induction of cellular immune responses.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=189023Documentos Relacionados
- Vaccinia virus vectors: new strategies for producing recombinant vaccines.
- Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines.
- Attenuated Mengo virus as a vector for immunogenic human immunodeficiency virus type 1 glycoprotein 120.
- Local and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccines.
- Soluble recombinant influenza vaccines.
